Meet PathGen! This Indonesian startup is making it accessible and affordable to diagnose cancer and other diseases. Now, they just raised an undisclosed funding round.
Investor check. East Ventures and Royal Group Indonesia joined in!
🩺 Why it matters
Low-cost solutions are key in lower and middle-income countries. Here, access to testing is extremely low to begin with.
Easy and affordable access to testing allows patients to detect cancer early and promote better patient outcomes.
🧪 The Path(Gen) ahead
PathGen iscurrently developing easy-to-use low-cost PCR-based genetic testing kits for several cancers, like colorectal, lung, nasopharynx, and cervical cancers.
Apart from these, they’re also developing an AI-powered digital pathology platform for precise diagnoses, biomarker tracking, and resource sharing.
💰 What’s with the $$$?
They’ll invest in R&D, advancing their tech, market expansion, operations, and more.
The newsletter that keeps you up-to-date on the top stories on tech and business in Southeast Asia. It's fun, quick and free.